News & Events

News and Events

2016

Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula

September 6, 2016

SAN JOSE, Calif., September 6, 2016 -- Teikoku Pharma USA Inc. ("TPU") today announced that it has entered into an exclusive license agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (“Luoxin”) to market, sell and distribute TPU's Docetaxel Injection, Non-Alcohol Formula in China.

READ MORE

Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula

February 2, 2016

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”). Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

READ MORE

2015

Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula

December 28, 2015

San Jose, Calif., Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

READ MORE

Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula

October 15, 2015

Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. to market, sell, and distribute TPU’s Docetaxel Injection, Non-Alcohol Formula in the United States.

READ MORE

Teikoku Pharma USA Announces New Drug Application to The U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula

March 24, 2015

Teikoku Pharma USA (TPU) announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA.

READ MORE